# A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

> **NCT04305197** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** ICP-022
- **DRUG:** ICP-022
- **DRUG:** ICP-022
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04305197
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-09
- **Primary completion:** 2022-04-28
- **Final completion:** 2022-04-28
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305197, "A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04305197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*